Soligenix, Inc. (SNGX)
Stock Price:
$2.13 USD
-0.04 (-1.62%)
Updated Aug 12, 2020 11:48 AM EDT - Market open
Key Info
| Market Cap |
61.54M |
| Revenue (ttm) |
4.41M |
| Net Income (ttm) |
-15.30M |
| Shares Out |
28.96M |
| EPS (ttm) |
-0.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$2.13 |
| Previous Close |
$2.16 |
| Change ($) |
-0.04 |
| Change (%) |
-1.62% |
| Day's Open |
2.17 |
| Day's Range |
2.04 - 2.22 |
| Day's Volume |
492,112 |
| 52-Week Range |
0.85 - 3.54 |
More Stats
| Market Cap |
61.54M |
| Enterprise Value |
54.43M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.96M |
| Float |
26.48M |
| EPS (basic) |
-0.72 |
| EPS (diluted) |
-0.74 |
| FCF / Share |
-0.34 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
327,250 |
| Short Ratio |
0.29 |
| Short % of Float |
2.28% |
| Beta |
1.36 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
13.96 |
| PB Ratio |
18.62 |
| Revenue |
4.41M |
| Operating Income |
-16.71M |
| Net Income |
-15.30M |
| Free Cash Flow |
-7.94M |
| Net Cash |
7.11M |
| Net Cash / Share |
0.25 |
| Gross Margin |
24.09% |
| Operating Margin |
-379.05% |
| Profit Margin |
-346.90% |
| FCF Margin |
-180.13% |
| ROA |
-107.87% |
| ROE |
-347.82% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.42*
(108.00% upside)
Low
2.00
Current: $2.13
High
7.25
Target: 4.42
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 4.63 | 5.24 | 5.43 | 10.45 | 8.77 | 7.04 | 3.22 | 3.14 | 7.66 | 1.95 |
| Revenue Growth | -11.67% | -3.52% | -48.01% | 19.16% | 24.5% | 118.45% | 2.53% | -58.96% | 293.44% | - |
| Gross Profit | 1.06 | 0.64 | 1.12 | 2.02 | 1.89 | 1.73 | 0.68 | 0.55 | 5.55 | 0.31 |
| Operating Income | -10.54 | -9.06 | -7.59 | -5.71 | -7.11 | -10.76 | -7.16 | -4.69 | -2.96 | -7.88 |
| Net Income | -9.36 | -8.90 | -7.15 | -3.25 | -7.83 | -6.71 | -10.06 | -4.16 | -2.38 | -7.39 |
| Shares Outstanding | 19.38 | 13.18 | 6.14 | 3.48 | 2.61 | 2.06 | 1.55 | 1.11 | 1.10 | 1.01 |
| Earnings Per Share | -0.48 | -0.68 | -1.16 | -1.34 | -3.00 | -4.30 | -6.50 | -3.70 | -2.20 | -7.30 |
| Operating Cash Flow | -7.51 | -7.24 | -6.51 | -4.98 | -5.39 | -2.47 | -4.46 | -2.64 | -1.95 | -5.73 |
| Capital Expenditures | -0.02 | - | -0.03 | -0.01 | -0.02 | -0.05 | -0.02 | - | - | -0.01 |
| Free Cash Flow | -7.53 | -7.25 | -6.54 | -4.99 | -5.41 | -2.52 | -4.47 | -2.64 | -1.95 | -5.74 |
| Cash & Equivalents | 5.42 | 8.98 | 7.81 | 8.77 | 4.92 | 5.53 | 5.86 | 3.36 | 6.00 | 7.45 |
| Total Debt | 0.13 | - | - | - | 0.29 | - | - | - | - | - |
| Net Cash / Debt | 5.29 | 8.98 | 7.81 | 8.77 | 4.63 | 5.53 | 5.86 | 3.36 | 6.00 | 7.45 |
| Assets | 7.78 | 10.49 | 9.55 | 10.27 | 7.39 | 6.95 | 8.27 | 4.71 | 8.22 | 9.27 |
| Liabilities | 6.32 | 4.21 | 3.23 | 2.87 | 7.41 | 7.11 | 10.04 | 1.15 | 1.43 | 1.91 |
| Book Value | 1.46 | 6.28 | 6.32 | 7.40 | -0.02 | -0.15 | -1.77 | 3.55 | 6.79 | 7.36 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Soligenix, Inc. |
| Country |
United States |
| Employees |
15 |
| CEO |
Christopher J. Schaber |
Stock Information
| Ticker Symbol |
SNGX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SNGX |
| IPO Date |
June 15, 1987 |
Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.